ESTRO 2024 - Abstract Book

S1994

Clinical - Mixed sites, palliation

ESTRO 2024

RT: radiotherapy, PTV: planning target volume, ALC: absolute lymphocyte count

Figure 1. Overall survival in patients with and without severe lymphopenia

Conclusion:

Pretreatment lymphocyte count predicted the development of severe lymphopenia in patients with advanced cancers treated with SBRT and immunotherapy. Severe lymphopenia was correlated with a decreased OS. In this heavily pretreated population, baseline lymphocyte count might be a reliable surrogate reflecting the compromised immune system of these patients due to prior therapies and/or advanced disease. Clinical validation of strategies to preserve and boost the lymphocyte reserves before and during treatment are awaited.

Keywords: Radiation-induced lymphopenia, SBRT, immunotherapy

References:

1. Venkatesulu, B. P., Mallick, S., Lin, S. H. & Krishnan, S. A systematic review of the influence of radiation-induced lymphopenia on survival outcomes in solid tumors. Crit. Rev. Oncol. Hematol. 123, 42 – 51 (2018).

2. de Kermenguy, F. et al. Radio-induced lymphopenia in the era of anti-cancer immunotherapy. Int. Rev. Cell Mol. Biol. 378, 1 – 30 (2023).

3. Thor, M. et al. Pre-treatment immune status predicts disease control in NSCLCs treated with chemoradiation and durvalumab. Radiother. Oncol. 167, 158 – 164 (2022).